Abstract Background: Cannabis and its derivatives show encouraging therapeutic effects in the treatment of various diseases. However, further studies are…
Abstract Aim: Cannabis-based medication has recently been made available in the NHS for reducing pain and spasticity in patients with…
Abstract Spasticity and its related symptoms of spasms, pain, sleep disturbance and bladder dysfunction are common in persons with multiple…
Abstract Background: Glioblastoma (GBM) is the most common adult malignant brain tumour, with an incidence of 5 per 100,000 per…
Abstract Background: Spasticity affects 54% of multiple sclerosis (MS) patients at disease onset, but this rate gradually increases with disease…
Abstract Background: Cannabinoids may be useful to treat pain, epilepsy and spasticity, although they may bear an increased risk of…
Abstract Background: Nabiximols is a cannabis-based drug to treat spasticity-associated symptoms currently approved for patients with multiple sclerosis only. Cannabinoids…
Abstract The antineoplastic effects of cannabis have been known since 1975. Since the identification of the components of the endogenous…
Abstract Increasing prescription numbers of cannabis-based medicines raise the question of whether uptake of these medicines can be distinguished from…
Abstract The phytocannabinoid-based medicine Sativex® is currently marketed for the treatment of spasticity and pain in multiple sclerosis patients and…